Diroximel fumarate in the treatment of multiple sclerosis

Elise Jonasson, Tobias Sejbaek*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review


Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the levels generated from dimethyl fumarate (DMF) treatment. The efficacy and safety profiles of DRF are expected to be similar to the well-established profiles of DMF. The metabolism of DRF leads to lower concentration of methanol in the small intestine than with DMF and thus reduced severity and frequency of gastrointestinal adverse events. DRF seems a promising alternative to DMF and other first-line therapies for multiple sclerosis. The current review is based on the two existing Phase III trials of DRF: the interim analysis of the EVOLVE-MS-1 trial and the completed EVOLVE-MS-2 trial.

Original languageEnglish
JournalNeurodegenerative Disease Management
Issue number5
Pages (from-to)267-276
Publication statusPublished - Oct 2020


Dive into the research topics of 'Diroximel fumarate in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this